Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types
IntroductionImmunotherapy has shown positive response in many patients with microsatellite instable (MSI-H) tumors, but its effectiveness in microsatellite stable (MSS) tumors remains limited. We hypothesize that tumor mutational burden (TMB) can help …